Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis

Indian Journal of Medical Sciences

Volumn 60, Issue 8, 2006, Pages 318-326

  Antony, T ^a   Jose, V ^a,b   Paul, B ^a   Thomas, T ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

DAS28; Drug therapy; EULAR; Humans; Leflunomide; Methotrexate; Refractory; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHLOROQUINE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD EXAMINATION; CHI SQUARE TEST; CLINICAL TRIAL; DERMATITIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVALUATION; FEMALE; FISHER EXACT TEST; HAIR LOSS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSENSITIVITY; INDIA; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; REMISSION; RHEUMATOID ARTHRITIS; SKIN DISCOLORATION; TERTIARY HEALTH CARE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 33746931717     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.26608     Document Type: Article

References (32)

1. th ed. McGraw Hill: New York; 2003. p. 1928-37.
2. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
3. Handa R. Management of rheumatoid arthritis. Natl Med J India 2004;17:143-51.
4. th ed. Churchill Livingstone: London; 2003. p. 663-77.
5. Popovic M, Stefanovic D, Pejnovic N, Popovic R, Glisic B, Obradovic S, et al. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine and levamisole) in patients with rheumatoid arthritis. Transplant Proc 1998;30:4135-6.
6. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
7. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999;42:1322-8.
8. Hochberg MC, Chang RW, Dwosh I. The American College of Rheumatology 1991 revised criteria for the classification of global functional status of rheumatoid arthritis. Arthritis Rheumat 1992;35:498-502.
9. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts:Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
10. http://www.das-score.nl/www.das-score.nl/index.html
11. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life:results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
12. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
13. Smolen JS. Efficacy and safety of the new DMARD leflunomide: Comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol Suppl 1999;112:15-21.
14. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353:259-66.
15. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
16. Poor G, Strand V, Leflunomide Multinational Study Group. Efficacy and safety of leflunomide 10mg versus 20mg once daily in patients with active rheumatoid arthritis:multinational double-blind, randomized trial. Rheumatology 2004;43:744-9.
17. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomide and and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31:1521-31.
18. Edwards IR, Arsonson JK. Adverse drug reactions: Definitions, diagnosis and management. Lancet 2000;356:1255-9.
19. Mroczkowski PJ, Weinblatt ME, Kremer JM. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol 1999;17:S66-8.
20. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44:1984-92.
21. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year follow up study. Arthritis Rheum 2003;48:1513-20.
22. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
23. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:495-505.
24. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506-14.
25. Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001;30:135-42.
26. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72.
27. Van Roon EN, Jansen TL, Mourad L, Houtman PM, Bruyn GA, Griep EN, et al. Leflunomide in active rheumatoid arthritis: A prospective study in daily practice. Br J Clin Pharmacol 2004;58:201-8.
28. Jaimes-Hernandez J, Robles-San Roman M, Suarez-Otero R, Davalos-Zugasti ME, Arroyo-Borrego S. Rheumatoid arthritis treatment with weekly leflunomide: An open-label study. J Rheumatol 2004;31:235-7.
29. Jakez-Ocampo J, Richaud-Patin Y, Simon JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: An open pilot comparative study. Joint Bone Spine 2002;69:307-11.
30. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, et al. Leflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patients. Arthritis Rheum 2003;49:745-51.
31. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004;117:87-92.
32. Dougados M, Emery P, Lemmel EM, de la Serna R, Zerbini CA, Brin S, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: Relief 6-month data. J Rheumatol 2003;30:2572-9.